A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|June 1, 2004
- Volume 0 0
Dental Problems May Cause Headaches
Advertisement
Diet, stress, and fatigue may not be the only leading causes of headaches. Research has shown that a poorly aligned bite or missing teeth may lead to frequent headaches. Patients and dentists should look for the following signs that the mouth is the culprit behind headaches:
- Pain behind the eyes
- Sore jaw muscles
- Teeth grinding
- Clicking or popping of jaw joints
- Earaches or ringing in the ears
- Dizziness
Experts recommend that patients who have frequent headaches along with these symptoms visit their dentist.
Articles in this issue
over 22 years ago
ACE Inhibitors and ARBs in Patients with Kidney Diseaseover 22 years ago
Drug Use While Breast-Feedingover 22 years ago
News on Drug Discount Cardsover 22 years ago
Management of Thyroid Disordersover 22 years ago
COMPOUNDING HOTLINEover 22 years ago
Prescription Drug Abuse Scams?Part 2over 22 years ago
Enhanced Warfarin Response and Antibioticsover 22 years ago
Large Jury Award Not the Result of Passion or Prejudiceover 22 years ago
New Study Suggests Aspirin Lowers Risk for Breast Cancerover 22 years ago
Emergency Contraception: Just the FactsAdvertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
5